News
Displaying 1–10 of 563
-
In the Press
Four-year cohort will enroll participants with inherited retinal diseases caused by mutations in the RHO gene. Study is intended to deepen understanding of disease progression and inform future clinical trial design in rhodopsin-associated retinal disease.
-
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Research NewsData monitoring committee recommends proceeding with registration-enabling study for ATSN-201
-
Foundation News
The gathering will be held June 12–13 and will convene global communities impacted by blinding diseases, alongside researchers, clinicians, patient advocates, and industry partners to foster collaboration, innovation, and hope.
-
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing
Research NewsMeiraGTx has acquired bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), and plans to file for regulatory approval in the U.S., Europe, and Japan, with a potential launch in 2027.
-
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research on retinitis pigmentosa.
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
-
Stargardt Disease Research Advances
Research NewsRecent developments in research on Stargardt disease.
-
Age-Related Macular Degeneration Research Advances
Research NewsRecent developments in research on age-related macular degeneration.
-
Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline
Research NewsStrategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
